TIAA Kaspick’s Voyager Therapeutics VYGR Stock Holding History

TIAA Kaspick’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-27,775	Closed	-$261K	–	17
2018 Q4	$261K	Buy	+27,775	New	+$356K	0.12%	12

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

TIAA Kaspick's VYGR Position: Q1 2019 in Review

TIAA Kaspick sold out of Voyager Therapeutics (VYGR) in Q1 2019, closing a stake of 27,775 shares — an estimated $261K sold.

TIAA Kaspick first reported a position in VYGR in Q4 2018 and held it in 1 quarter. The position peaked at $261K in Q4 2018. 111 funds tracked by Wall St. Rank hold VYGR as of Q1 2019.

TIAA Kaspick reported no remaining Voyager Therapeutics position as of Q1 2019 after selling out during the quarter.
TIAA Kaspick sold 27,775 Voyager Therapeutics shares in Q1 2019, an estimated $261K.
TIAA Kaspick first reported a position in Voyager Therapeutics in Q4 2018 and held it in 1 quarter.
TIAA Kaspick's Voyager Therapeutics position peaked at $261K in Q4 2018.
111 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2019.

Based on TIAA Kaspick's 13F filing for Q1 2019, filed 8 May 2019.